Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Guggenheim Downgrades Rubius Therapeutics to Neutral

Guggenheim analyst Michael Schmidt downgrades Rubius Therapeutics (NASDAQ:RUBY) from Buy to Neutral.
byBenzinga Newsdesk
September 13, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Guggenheim analyst Michael Schmidt downgrades Rubius Therapeutics (NASDAQ:RUBY) from Buy to Neutral.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Renalytix Highlights Study Results For Co.’s KidneyIntelX Published In ‘The American Journal Of Nephrology,’ Showed ‘KidneyIntelX successfully monitors patient response to SGLT2 therapy in 1,325 CANagliflozin CardioVAScular Assessment…’

By Benzinga Newsdesk
Today, 8:59 AM
Renalytix (NASDAQ:RNLX) (LSE: RENX) announced the publication of positive study results for KidneyIntelX™ as a risk monitoring tool to assess impact and response to novel treatments for patients with

RNLX